WALTHAM, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NURO, Financial) today reported that it will present two scientific posters at the upcoming 2018 American Academy of Pain Medicine (AAPM) Annual Meeting to be held in Vancouver, Canada, April 26-28.
The two posters are titled:
“Does Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation Provide Analgesia Beyond Application Site?”
This poster is a re-analysis of previously published data that further confirms the widespread analgesic effects of Quell® neurostimulation. The abstract is available at:
painmed.org/2018scientific-abstracts/rehabilitation/#abstract288
“Levels and Predictors of Activity in Users of Wearable Neurostimulators with Chronic Pain.”
This poster leverages the unique data that is collected in the Quell Health Cloud to explore activity levels in Quell users. A decrease in activity is associated with chronic pain and contributes to further pain and poor health. Over half of the Quell users in the study dataset walked more than 1 mile (2000 steps) daily while wearing their device indicating that many Quell users are active while receiving therapy. The abstract is available at:
painmed.org/2018scientific-abstracts/rehabilitation/#abstract289
"We are pleased to have the opportunity to present additional Quell data at AAPM, which is one of the premier scientific and clinical meetings in pain medicine,” said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix.
About Quell
Quell is an advanced, wearable technology for treating chronic pain. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud, which provides customized feedback and powers one of the world’s largest chronic pain databases. Quell is available online and through select retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more
information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
[email protected]
Source: NeuroMetrix, Inc.
